Association of SGLT-2 inhibition with size of myocardial infarction in patients with type 2 diabetes mellitus: a retrospective analyis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032432

Enrollment

1000

Registered

2023-08-07

Start date

2023-08-04

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E11.9

Interventions

Group 1: Patients with diabetes mellitus and myocardial infarction under SGLT2-inhibitor therapy or without in the University heart Center Freiburg- Bad Krozingen.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Acute myocardial infarction at presentation (ECG and/or laboratory findings) and diabetes mellitus type 2 Ongoing therapy with an SGLT-2i or control patients without SGLT-2i

Exclusion criteria

Exclusion criteria: Out of hospital cardiac arrest

Design outcomes

Secondary

Measure	Time frame
BIOMARKERS • Maximum, observed serum level (max. 72 hours after revascularization): • Troponin (normalized on the myocardial area at risk) • CK-MB (normalized on the myocardial area at risk) • proBNP ECHOCARDIOGRAM • LV-EF during the index hospitalisation (prior discharge) • Diastolic LV-dysfunction (E/e´ mean > 14, LA > 34 ml/m2, TR velocity > 2,9 m/s) CLINICAL OUTCOMES: • In-hospital survival • Killip class 3 or 4 during the index hospitalization • Killip class 2 during the index hospitalization • Life-threatening ventricular arrhythmiaStent thrombosis (Type 4b MI per UDMI) during index hospitalisation • acute kidney injury assessed by elevation of serum Creatinin and/or decrease of eGFR (according to the RIFLE criteria 10.1186/cc2872) • Days hospitalized • Days ICU treatment	—

Measure

Time frame

BIOMARKERS • Maximum, observed serum level (max. 72 hours after revascularization): • Troponin (normalized on the myocardial area at risk) • CK-MB (normalized on the myocardial area at risk) • proBNP ECHOCARDIOGRAM • LV-EF during the index hospitalisation (prior discharge) • Diastolic LV-dysfunction (E/e´ mean > 14, LA > 34 ml/m2, TR velocity > 2,9 m/s) CLINICAL OUTCOMES: • In-hospital survival • Killip class 3 or 4 during the index hospitalization • Killip class 2 during the index hospitalization • Life-threatening ventricular arrhythmiaStent thrombosis (Type 4b MI per UDMI) during index hospitalisation • acute kidney injury assessed by elevation of serum Creatinin and/or decrease of eGFR (according to the RIFLE criteria 10.1186/cc2872) • Days hospitalized • Days ICU treatment

—

Primary

Measure	Time frame
The maximum observed serum level of cardiac TroponinT in the first 72 hours after revascularization normalized on the myocardial area at risk as determined by coronary angiography.	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026